588 results on '"Roobol, Monique J."'
Search Results
2. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
3. From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life
4. The transition from transrectal to transperineal prostate biopsy without antibiotic prophylaxis: Cancer detection rates and complication rates
5. Externe validatie van de Prostaatwijzer binnen een Nederlands klinisch hoogrisicocohort
6. Predictive Models for Assessing Patients’ Response to Treatment in Metastatic Prostate Cancer: A Systematic Review
7. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data
8. How Can We Improve Patient-Clinician Communication for Men Diagnosed with Prostate Cancer?
9. Association between circulating inflammatory markers and adult cancer risk: a Mendelian randomization analysis
10. Systematic Review on the Cost Effectiveness of Prostate Cancer Screening in Europe
11. Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam
12. External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort
13. The Europa Uomo Patient Reported Outcome Study 2.0—Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making
14. Relationship Between Baseline Prostate-specific Antigen on Cancer Detection and Prostate Cancer Death: Long-term Follow-up from the European Randomized Study of Screening for Prostate Cancer
15. A Detailed Evaluation of the Effect of Prostate-specific Antigen–based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer
16. Urinary Incontinence and Sexual Function After the Introduction of NeuroSAFE in Radical Prostatectomy for Prostate Cancer
17. The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam
18. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting
19. Interaction of MRI and active surveillance in prostate cancer: Time to re-evaluate the active surveillance inclusion criteria
20. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
21. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer—Data from the International Multicenter Prospective PRIAS Study
22. Improving Guideline Adherence in Urology
23. Detailed Evaluation of Androgen Deprivation Overtreatment in Prostate Cancer Patients Compared to the European Association of Urology Guidelines Using Long-term Data from the European Randomised Study of Screening for Prostate Cancer Rotterdam
24. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative
25. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium
26. Cross-cultural differences in men on active surveillance’ anxiety: a longitudinal comparison between Italian and Dutch patients from the Prostate cancer Research International Active Surveillance study
27. Improving the prediction of biochemical recurrence after radical prostatectomy with the addition of detailed pathology of the positive surgical margin and cribriform growth
28. Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data
29. Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
30. Evolution of European prostate cancer screening protocols and summary of ongoing trials.
31. Intervention-related Deaths in the European Randomized Study of Screening for Prostate Cancer
32. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer
33. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer
34. Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients
35. Health-related quality of life in Japanese low-risk prostate cancer patients choosing active surveillance: 3-year follow-up from PRIAS-JAPAN
36. Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients
37. Urine spermine and multivariable Spermine Risk Score predict high-grade prostate cancer
38. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
39. Timing van de PSMA PET/CT-scan bij biochemisch recidief na radicale prostatectomie
40. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men
41. Clinicopathological characteristics of glomeruloid architecture in prostate cancer
42. Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance Initiative
43. Clinically significant prostate cancer detection and segmentation in low-risk patients using a convolutional neural network on multi-parametric MRI
44. Decision aid and cost compensation influence uptake of PSA-based early detection without affecting decisional conflict: a cluster randomised trial
45. Comparison of Tumor Volume Parameters on Prostate Cancer Biopsies
46. Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions
47. Distribution of Prostate Imaging Reporting and Data System score and diagnostic accuracy of magnetic resonance imaging–targeted biopsy: comparison of an Asian and European cohort
48. Informed decision-making based on a leaflet in the context of prostate cancer screening
49. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis
50. Performance of magnetic resonance imaging‐based prostate cancer risk calculators and decision strategies in two large European medical centres.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.